How published research underpinned a cancer therapy awareness campaign
Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment -and wanted to better understand the disease and treatment challenges faced by both patients and physicians across Asia. In addition, our client also wanted to establish KOLs to advocate for the management of OM by raising the overall disease awareness, understanding and provision of better support for the wider healthcare community. In order to achieve this our client intended to submit the research for publication in a leading medical journal.
How integrated insights supported a biologic launch strategy across multiple indications
Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their new product. They wanted to use the insights to develop the launch strategy across markets and across indications, and also support the negotiation team with training.
How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy
Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests or therapies. Time constraints limited the ability for a full qualitative phase.
How buyer insights supported the development of an effective market strategy
Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to understand how new medicines are added to the guidelines and how they are evaluated and funded. They also needed to gain an understanding of stakeholders’ reactions to their product, the drivers and barriers to use and expectations regarding pricing.
How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market
Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led by established 1st generation tyrosine kinase inhibitors (TKIs). There were several scenarios that the client wanted to test, including impact of launch order and the impact of future 3rd generation TKIs on the drug’s market potential. The research was complicated by the fact that both the clients (and likely key future competitors’), profile was as yet unknown – the research therefore needed to assess likely share while taking account of multiple moving parts.